{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T21:02:46Z","timestamp":1789506166326,"version":"build-2803163510"},"reference-count":34,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T00:00:00Z","timestamp":1765497600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Prostate International"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.prnil.2025.12.002","type":"journal-article","created":{"date-parts":[[2025,12,27]],"date-time":"2025-12-27T16:21:11Z","timestamp":1766852471000},"page":"89-96","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["AR-V7 expression in primary non-metastatic prostate cancer and its role in disease progression following initial therapy: a systematic review and meta-analysis"],"prefix":"10.1016","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5310-6210","authenticated-orcid":false,"given":"Marcelo","family":"Quintanilha","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hil\u00e1ria","family":"Saugo Faria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrique","family":"Leal de Oliveira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leo","family":"Meira Martins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilma","family":"Simoni Brum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.prnil.2025.12.002_bib2","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1111\/his.13712","article-title":"Defining clinically significant prostate cancer on the basis of pathological findings","volume":"74","author":"Matoso","year":"2019","journal-title":"Histopathology"},{"key":"10.1016\/j.prnil.2025.12.002_bib3","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1016\/j.eururo.2012.01.050","article-title":"Upgrading and downgrading of prostate cancer from biopsy to radical prostatectomy: incidence and predictive factors using the modified Gleason grading system and factoring in tertiary grades","volume":"61","author":"Epstein","year":"2012","journal-title":"Eur Urol"},{"issue":"1\u20132","key":"10.1016\/j.prnil.2025.12.002_bib4","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/S0303-7207(02)00364-7","article-title":"Molecular action of androgens","volume":"198","author":"Gobinet","year":"2002","journal-title":"Mol Cell Endocrinol"},{"issue":"12","key":"10.1016\/j.prnil.2025.12.002_bib5","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1038\/nrc4016","article-title":"Androgen receptor signaling in castration-resistant prostate cancer: resistance mechanisms and therapeutic approaches","volume":"15","author":"Watson","year":"2015","journal-title":"Nat Rev Cancer"},{"issue":"11","key":"10.1016\/j.prnil.2025.12.002_bib6","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1056\/NEJMoa1315815","article-title":"AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer","volume":"371","author":"Antonarakis","year":"2014","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.prnil.2025.12.002_bib7","first-page":"124","article-title":"AR-V7 in advanced prostate cancer: implications for treatment choices","volume":"33","author":"Hornberger","year":"2019","journal-title":"Oncology"},{"key":"10.1016\/j.prnil.2025.12.002_bib8","first-page":"7135","article-title":"Androgen receptor variants and prostate cancer: new insights into molecular mechanisms and clinical implications","volume":"39","author":"Zhang","year":"2020","journal-title":"Oncogene"},{"issue":"71","key":"10.1016\/j.prnil.2025.12.002_bib9","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"Br Med J"},{"issue":"6822","key":"10.1016\/j.prnil.2025.12.002_bib10","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1038\/35057062","article-title":"Initial sequencing and analysis of the human genome","volume":"409","author":"Lander","year":"2001","journal-title":"Nature"},{"issue":"31","key":"10.1016\/j.prnil.2025.12.002_bib11","doi-asserted-by":"crossref","first-page":"31997","DOI":"10.18632\/oncotarget.5585","article-title":"Differential regulation of metabolic pathways by androgen receptor (AR) and its constitutively active splice variant, AR-V7, in prostate cancer cells","volume":"6","author":"Shafi","year":"2015","journal-title":"Oncotarget"},{"issue":"6","key":"10.1016\/j.prnil.2025.12.002_bib12","first-page":"387","article-title":"Role of androgens in the development and progression of prostate cancer","volume":"46","author":"Smith","year":"2018","journal-title":"Urol Res"},{"key":"10.1016\/j.prnil.2025.12.002_bib13","first-page":"161.e19","article-title":"Tissue expression of androgen receptor splice variant 7 at radical prostatectomy predicts risk of progression in untreated nonmetastatic prostate cancer","volume":"36","author":"Sciarra","year":"2018","journal-title":"Urol Oncol: Semin Original Invest."},{"key":"10.1016\/j.prnil.2025.12.002_bib14","first-page":"251","article-title":"Overexpression of nuclear AR-V7 protein in primary prostate cancer is an independent negative prognostic marker in men with high-risk disease receiving adjuvant therapy","volume":"99","author":"Chen","year":"2021","journal-title":"Oncology"},{"key":"10.1016\/j.prnil.2025.12.002_bib15","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Ac Sterne","year":"2016","journal-title":"The BMJ"},{"key":"10.1016\/j.prnil.2025.12.002_bib16","volume":"2","author":"Higgins Julian","year":"2019"},{"key":"10.1016\/j.prnil.2025.12.002_bib17","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s40364-021-00276-x","article-title":"Androgen receptor splice variant 7 detected by immunohistochemistry is an independent poor prognostic marker in men receiving adjuvant androgen-deprivation therapy after radical prostatectomy","volume":"9","author":"Ouyang","year":"2021","journal-title":"Biomark Res"},{"key":"10.1016\/j.prnil.2025.12.002_bib18","article-title":"Expression of AR-V7 (Androgen Receptor Variant 7) protein in granular cytoplasmic structures is an independent prognostic factor in prostate cancer patients","volume":"9","author":"K\u00f6nig","year":"2021","journal-title":"Biomark Res"},{"key":"10.1016\/j.prnil.2025.12.002_bib19","doi-asserted-by":"crossref","first-page":"2158","DOI":"10.1016\/j.juro.2012.08.014","article-title":"Transcript levels of androgen receptor variant AR-V1 or AR-V7 do not predict recurrence in patients with prostate cancer at indeterminate risk for progression","volume":"188","author":"Zhao","year":"2012","journal-title":"J Urol. dez."},{"key":"10.1016\/j.prnil.2025.12.002_bib20","article-title":"Antibody selection influences the detection of AR-V7 in primary prostate cancer","volume":"24","author":"Kaczorowski","year":"2020","journal-title":"Cancer Treat Res Commun"},{"key":"10.1016\/j.prnil.2025.12.002_bib21","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1038\/modpathol.2017.74","article-title":"Androgen-receptor splice variant-7-positive prostate cancer: a novel molecular subtype with markedly worse androgen-deprivation therapy outcomes in newly diagnosed patients","volume":"31","author":"Li","year":"2018","journal-title":"Mod Pathol."},{"key":"10.1016\/j.prnil.2025.12.002_bib22","doi-asserted-by":"crossref","first-page":"3223","DOI":"10.3390\/cells10113223","article-title":"Cell-free DNA variant sequencing using plasma and AR-V7 testing of circulating tumor cells in prostate cancer patients","volume":"10","author":"Lieb","year":"2021","journal-title":"Cells"},{"issue":"1","key":"10.1016\/j.prnil.2025.12.002_bib24","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.jviscsurg.2013.10.001","article-title":"Title of the article","volume":"151","author":"Fiteni","year":"2014","journal-title":"J Visc Surg"},{"issue":"8","key":"10.1016\/j.prnil.2025.12.002_bib25","first-page":"622","article-title":"Impact of AR-V7 expression on overall survival for patients with metastatic prostate cancer","volume":"52","author":"Yuanyuan","year":"2014","journal-title":"Zhonghua Wai Ke Za Zhi"},{"issue":"11","key":"10.1016\/j.prnil.2025.12.002_bib26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1001\/jamaoncol.2016.1828","article-title":"Association of AR-V7 on circulating tumor cells as a treatment-specific biomarker with outcomes and survival in castration-resistant prostate cancer","volume":"2","author":"Scher","year":"2016","journal-title":"JAMA Oncol"},{"issue":"4","key":"10.1016\/j.prnil.2025.12.002_bib27","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.euf.2017.01.004","article-title":"Prognostic value of androgen receptor splice variant 7 in the treatment of castration-resistant prostate cancer with next generation androgen receptor signal inhibition: a systematic review and meta-analysis","volume":"4","author":"Li","year":"2018","journal-title":"Eur Urol Focus"},{"issue":"3","key":"10.1016\/j.prnil.2025.12.002_bib28","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/s41391-020-0217-3","article-title":"Androgen receptor variant-driven prostate cancer II: advances in laboratory investigations","volume":"23","author":"Lu","year":"2020","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"11","key":"10.1016\/j.prnil.2025.12.002_bib29","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1056\/NEJMoa1315815","article-title":"AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer","volume":"371","author":"Antonarakis","year":"2014","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.prnil.2025.12.002_bib30","first-page":"531","article-title":"Nuclear-specific AR-V7 protein localization is necessary to guide treatment selection in metastatic castration-resistant prostate cancer","volume":"74","author":"Scher","year":"2018","journal-title":"Eur Urol"},{"issue":"2","key":"10.1016\/j.prnil.2025.12.002_bib31","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1080\/14737159.2018.1427068","article-title":"CTC-derived AR-V7 detection as a prognostic and predictive biomarker in advanced prostate cancer","volume":"18","author":"Bastos","year":"2018","journal-title":"Expert Rev Mol Diagn"},{"issue":"5","key":"10.1016\/j.prnil.2025.12.002_bib32","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1001\/jamaoncol.2015.1341","article-title":"Androgen receptor splice variant 7 and efficacy of taxane chemotherapy in patients with metastatic castration-resistant prostate cancer","volume":"1","author":"Antonarakis","year":"2015","journal-title":"JAMA Oncol"},{"issue":"11","key":"10.1016\/j.prnil.2025.12.002_bib33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1001\/jamaoncol.2016.1828","article-title":"Association of AR-V7 on circulating tumor cells as a treatment-specific biomarker with outcomes and survival in castration-resistant prostate cancer","volume":"2","author":"Scher","year":"2016","journal-title":"JAMA Oncol"},{"issue":"11","key":"10.1016\/j.prnil.2025.12.002_bib34","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1056\/NEJMoa1315815","article-title":"AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer","volume":"371","author":"Antonarakis","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.prnil.2025.12.002_bib35","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.prnil.2023.12.002","article-title":"Real-world effects of novel androgen receptor axis-targeted agents on oncological outcomes in non-metastatic castration-resistant prostate cancer: a multi-institutional retrospective study","volume":"12","author":"Fujita","year":"2024","journal-title":"Prostate Int"},{"issue":"5","key":"10.1016\/j.prnil.2025.12.002_bib36","doi-asserted-by":"crossref","first-page":"416","DOI":"10.4111\/icu.20250147","article-title":"Establishing consensus recommendations for metastatic hormone-sensitive prostate cancer in South Korea: a modified Delphi study","volume":"66","author":"Joung","year":"2025","journal-title":"Investig Clin Urol"}],"container-title":["Prostate International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2287888225001187?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2287888225001187?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T14:14:59Z","timestamp":1773843299000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2287888225001187"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S2287888225001187"],"URL":"https:\/\/doi.org\/10.1016\/j.prnil.2025.12.002","relation":{},"ISSN":["2287-8882"],"issn-type":[{"value":"2287-8882","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"AR-V7 expression in primary non-metastatic prostate cancer and its role in disease progression following initial therapy: a systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Prostate International","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.prnil.2025.12.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Asian Pacific Prostate Society. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}